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Nerve growth factor (NGF) is overexpressed not only in nervous system, but also in several types of cancers. However, the role of
NGF in oesophageal squamous cell carcinoma (OESCC) remains unclear. Here, we show the first evidence of NGF-TrkA autocrine
loop and clinical significance of NGF overexpression in OESCC. Immunohistochemical study of 109 OESCC specimens revealed that
NGF overexpression, found in 63 out of 109 patients (57.8%), was associated with lymph node metastasis, distant metastasis, higher
TNM stage, poorer tumour differentiation, and poorer survival. NGF overexpression was also associated with strong expression of
TrkA and negative expression of low-affinity neurotrophin receptor (p75NTR). Semiquantitative reverse transcription–polymerase
chain reaction (RT–PCR) of 19 surgical specimens showed upregulation of NGF mRNA in 17 out of 19 (89%) patients. All five
OESCC cell lines tested in vitro secreted detectable NGF in enzyme-linked immunosorbent assay, and expressed TrkA and p75NTR
on RT–PCR and Western blot. The motility of HSA/c, one of the OESCC cell lines overexpressing NGF, was significantly decreased
by either neutralising anti-NGF antibody, an inhibitor of TrkA, or NGF-small interfering RNA in transwell migration assay. Our findings
suggest that NGF is of potential interest not only as a prognostic factor, but also as a novel therapeutic target in OESCC.
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Oesophageal squamous cell carcinoma (OESCC) is one of the most
lethal malignancies in the world including Japan, with a 5-year
survival rate of 20–30% after curative surgery (Isono et al, 1991;
Pisani et al, 1999). One of the reasons for poor prognosis is that
OESCC is frequently associated with extensive local invasion or
regional lymph node metastasis, even at initial diagnosis.
Improved treatments derived from a better understanding of the
biological basis of OESCC are now awaited.
We previously reported that the low-affinity neurotrophin
receptor (p75NTR) was expressed in a progenitor cell fraction of
human oesophageal keratinocyte (Okumura et al, 2003). Nerve
growth factor (NGF), one of the ligands of p75NTR, was originally
isolated for its ability to stimulate both the survival and
differentiation of peripheral neurons, later becoming the arche-
typal member of the neurotrophin family of polypeptides (Levi-
Montalcini, 1987; Barbacid, 1995). A major biological function of
NGF is the maintenance and survival of postmitotic neurons,
suggesting it may be useful for the treatment of neurodegenerative
diseases. In addition to its role in the development and
maintenance of neuronal cells, recent studies have shown that
NGF and its receptors are found and sometimes even over-
expressed outside the nervous system, where it may promote
cancer cell proliferation, growth, and invasion in several types of
cancer such as breast, pancreas, and prostate cancer (Pflug et al,
1995; Walch and Marchetti, 1999; Sakamoto et al, 2001a,b;
Schneider et al, 2001; Zhu et al, 2001, 2002; Kishibe et al, 2002;
Davidson et al, 2003; Dolle et al, 2003).
Nerve growth factor generates intracellular signals by interacting
with two classes of membrane receptors: the TrkA proto-oncogene
product p140trkA, which possesses intrinsic tyrosine kinase
activity, and a secondary receptor, p75NTR, which is a member
of the tumour necrosis factor-receptor family (Sofroniew et al,
2001). Nerve growth factor has also been found to be an autocrine
survival factor for B lymphocytes (Torcia et al, 1996), and Dolle
et al (2003) reported that NGF is involved in an autocrine loop in
breast cancer. In oesophageal cancer, however, only one small
clinical study on NGF expression has been reported (Zhu et al,
2000), which is very different from other studies in that they
showed downregulation of NGF in tumours with poorer differ-
entiation and in advanced stage. Thus, the significance of NGF
expression in OESCC remains unclear.
In this study, to determine whether NGF plays a role in OESCC,
we examined the expression of NGF, TrkA and p75NTR in 109
surgical specimens of OESCC. We also evaluated the role of NGF in
OESCC cell lines.
MATERIALS AND METHODS
Patients and surgical specimens
Frozen tissue specimens and paraffin-embedded sections were
obtained from surgically resected specimens from patients with
Received 20 February 2006; revised 16 May 2006; accepted 12 June
2006; published online 11 July 2006
*Correspondence: Dr Y Shimada; E-mail: shimada@kuhp.kyoto-u.ac.jp
British Journal of Cancer (2006) 95, 322–330
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sprimary OESCC. All patients underwent surgery at the Kyoto
University Hospital from 1984 to 2001. Among the 109 patients,
18 were women and 91 were men. The median age of the patients
was 63 years (range, 39–84 years). The median follow-up time of
survival was 40 months (range, 2–201 months). Information on
gender, age, stage of disease, and histopathological factors were
abstracted from the patients’ medical records. All tumours were
confirmed to be OESCC by pathologists in the Department of
Pathology at the Kyoto University Hospital. All of the cases were
staged according to the TNM Classification of Malignant Tumours,
Sixth edition, issued in 2002 (Sobin et al, 2002). Of the 109
patients, 15 patients (13.4%) were in stage I, 33 patients (30.3%) in
stage IIA-B, 39 patients (35.8%) in stage III, and 22 patients
(20.2%) were in stage IV. In this series, all cases with a positive M
factor had distant lymph node metastasis and there was no organ
metastasis. Written informed consent has been obtained from all
the patients for surgery and for the use of the resected samples for
research. The study protocol has been approved by the Institu-
tional Review Board of Kyoto University.
Immunohistochemical staining
Paraffin-embedded 4-mm-thick serial sections were autoclaved at
1211C in Target Retrieval Solution (Dako Cytomation, Kyoto,
Japan) for 5min, subjected to paraffin removal, and rehydrated.
The sections were immunostained with the Envision Plus kits/
HRP/DAB (Dako Cytomation) as recommended by the supplier.
Primary antibodies were diluted to 1:50 for anti-NGF rabbit
polyclonal antibody (sc-548, Santa Cruz Biotechnology Inc., CA,
USA), 1:400 for anti-TrkA rabbit polyclonal antibody (sc-118,
Santa Cruz Biotechnology Inc.), and 1:50 for anti-human p75NTR
monoclonal antibody (clone NGFR5; Dako Cytomation) with 1%
bovine serum albumin (BSA) (Nacalai Tesque Inc., Kyoto, Japan)
in phosphate-buffered saline (PBS), and the sections were
incubated for 1h at room temperature (NGF) or overnight at
41C (TrkA and p75NTR). After rinsing, the sections were incubated
with secondary antibody, counterstained with Mayer’s hema-
toxylin, dehydrated, and mounted. Nerve growth factor immuno-
reactivity in lymphocytes was used as an internal positive control in
every section. Sections incubated with blocking peptide (sc-548p,
Santa Cruz Biotechnology Inc.) served as a negative control for the
evaluation of NGF immunohistochemical staining.
Evaluation of immunohistochemical staining
Nerve growth factor was expressed diffusely in all OESCC, and
NGF staining intensity was evaluated in five areas of each slides
and graded into two groups; strong (stronger cytoplasmic staining
than smooth muscle of oesophagus) and weak expression (weaker
than smooth muscle cells). TrkA was expressed in the cytoplasm
and the membrane of OESCC. TrkA staining intensity was graded
into two groups; strong (positive membrane staining in more than
30% of OESCC or/and intense staining in cytoplasm of OESCC)
and weak/negative expression. p75NTR staining intensity was
graded into two groups; positive (positive membrane staining in
more than 10% of OESCC) and negative (staining less than 10%).
All slides were evaluated independently by two investigators (ST
and TO or YM) without any prior knowledge of each patient’s
clinical information. If the opinions of the two investigators
differed, agreement was reached by careful discussion.
Statistical analysis
The statistical significance of differences in NGF expression levels
and clinicopathologic factors or immunohistochemical staining
results of TrkA and p75NTR were analysed with w
2 tests. Overall
survival was defined as the duration of survival from the date of
the operation to the date of death because of cancer. The Kaplan–
Meier method was used to determine the probability of survival,
and data were analysed with the log-rank test. The Tukey–Kramer
multiple comparison test was used to evaluate the results of
migration assays. The software package StatView for Windows
version 5 (SAS Institute, Cary, NC, USA) was used for all analyses.
P-values o0.05 was considered statistically significant.
Extraction of total cellular RNA and semiquantitative
reverse transcription–polymerase chain reaction
Total RNA was extracted from frozen stored tissues of OESCC or
from cultured cells using acid guanidinium thiocyanate–phenol–
chloroform method. The amount of RNA extracted from each
sample was spectrophotometrically measured using a Gene Quanto
pro (Amersham Biosciences, Piscataway, NJ, USA). Then, precisely
2.5mg from each of the extracted RNA samples was used for first-
strand cDNA synthesis using a First Strand cDNA Synthesis kit
(Amersham, Buckinghamshire, UK) according to the manufac-
turer’s instructions. Specifically, TE solution was added to 2.5mgo f
extracted RNA to adjust each of the reaction mixture to the final
volume of 8ml and the mixture was denatured in 651C for 10min
and incubated on ice for 2min. Denatured samples were mixed
with 5ml of Bulk First-Strand Reaction Mixes, 1ml of DTT solution,
and 1ml of pd(N)6 primer and incubated in 371C for 60min and
951C for 5min for cDNA synthesis. Next 1ml of the first-strand
cDNA, 1ml of sense template (10mM), 1ml of antisense template
(10mM), 12.3ml of double distilled water, 0.6mlo f5 0m M MgCl2,2ml
of 10  polymerase chain reaction (PCR) Rxn buffer (Invitrogen
Corporation, Carlsbad, CA, USA), 2mlo f2 m M dNTP mix, and
0.1mlo fTaq DNA polymerase (Invitrogen Corporation) were used
in a total volume of 20ml to perform semiquantitative reverse
transcription–polymerase chain reaction (RT–PCR). Then, PCR
cycles were adjusted to make intensity of b-actin band from
respective samples to be nearly equal. Because the band intensity
of NGF turned out to be much lower than that of b-actin, on the
average, about 30 cycles needed to be run to clarify the difference
in expression levels of NGF and TrkA in different samples by
RT–PCR. For p75NTR, 25 cycles of PCR were performed for
semiquantification. PCR protocol was as follows: 1min denatura-
tion at 941C, 1min annealing at 621C (NGF) or 661C (TrkA) or
541C (p75NTR), and 1min elongation at 721C. Amplification
products were separated on 2% agarose gels and visualised by
ethidium bromide staining. A single 69-bp band amplified with
b-actin primers from respective cDNA served as an internal
control. Then, the signal intensity of each sample was calculated
with the ImageJ program version 1.36 (NIH, USA), and the ratio of
NGF (or TrkA, p75NTR) to b-actin was calculated. Next, NGF (or
TrkA, p75NTR) expression in each specimen was evaluated by
computing the ratio of NGF (or TrkA, p75NTR) band intensity
in tumour to that in the corresponding normal epithelium (T/N
ratio). The following PCR primers were used: NGF (403bp)
forward primer was 50-CCACACTGAGGTGCATAGCGTAA-30 and
reverse primer was 50-AGATGGGATGGGATGATGACCGCT-30;
TrkA (219bp) forward primer was 50-TCCGCCTCCATCATGGCTG
CCTT-30 and reverse primer was 50-CCCAAACTTGTTTCTCCGTC
CACA-30; p75NTR (230bp) forward primer was 50-TGAGTGCTG
CAAAGCCTGCAA-30 and reverse primer was 50-TCTCATCCTGG
TAGTAGCCGT-30; and b-actin (69bp) forward primer was
50- CCTGGCACCCAGCACAAT-30 and reverse primer was
50-GCCGATCCACACGGAGTACT-30.
Cell cultures
Five human OESCC cell lines (KYSE-150, KYSE-170, KYSE-1170,
HSA/c, and SUm/c) were used. These cell lines have been
established in our department and cultured in Ham’s F-12/RPMI
1640 with 2% (KYSE series) or 5% (HSA/c and SUm/c) fetal bovine
serum (FBS) as described previously (Shimada et al, 1992; Nakaji
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set al, 1999). For positive control, human breast cancer cell line,
MCF-7 was obtained from the Japanese Collection of Research
Bioresources and cultured in Eagle’s minimum essential medium
with nonessential amino acid with 1mM pyruvate, 1.5g1
 1
NaHCO3, 0.01gl
 1 insulin, and 10% FBS. Cells were incubated at
371C in a humidified atmosphere of 5% CO2 in air and
subconfluent cells were used in all experiments.
Western blot analysis
Cells were lysed in a sample buffer (10% glycerol, 20mM Tris-HCl,
pH 7.5, 1% NP-40, 100mM NaF, 1mM Na3VO4, 1mM phenylmethyl
sulfonyl fluoride; Complete Mini: Roche Diagnostics GmbH,
Mannheim, Germany) on ice. After sonication and centrifugation,
the supernatant was used for assay. The protein concentration was
estimated by the Bradford method using BCA Protein Assay
Reagent (Pierce, Rockford, IL, USA). After boiling, cell lysate
(80mg) was electrophoresed on 15–25% gradient polyacrylamide
gel (Daiichi Pure Chemicals, Tokyo, Japan) and transferred to
polyvinylidine diflouride membranes (Immobilon, Millipore,
Bedford, MA, USA) for NGF. For TrkA and p75NTR, 25mgo f
cell lysate was electrophoresed on 2–15% gradient polyacrylamide
gel (Daiichi Pure Chemicals). Membranes were blocked with 4%
BSA in 0.1% Tween-20 in Tris-buffered saline (20mM Tris, 150mM
NaCl, pH 7.6) for 1h in room temperature. A rabbit anti-NGF
polyclonal antibody (sc-548, Santa Cruz Biotechnology Inc.) was
used as primary antibody against NGF. The membrane was
incubated with primary antibody (diluted 1:800) at 41C overnight.
The membrane was subsequently incubated at room temperature
for 1h with horseradish peroxidase-linked goat anti-rabbit IgG
(Zymed, San Francisco, CA, USA) (diluted 1:4000). The final
detection of specific proteins was carried out with the use of
enhanced-chemiluminescence (ECL-plus) reagents (Amersham).
For p75NTR and TrkA, a rabbit anti-human p75NTR polyclonal
antibody (G332A, Promega, Madison, WI, USA) (diluted 1:1000)
and a rabbit anti-TrkA polyclonal antibody (sc-118, Santa Cruz
Biotechnology Inc.) (diluted 1:200) were used, respectively. For
phosphorylated TrkA, a mouse monoclonal anti-p-TrkA antibody
(sc-8058, Santa Cruz Biotechnology Inc.) (diluted 1:200) was used.
Lysate from the breast cancer cell line MCF-7 was used as a
positive control for NGF (Dolle et al, 2003), TrkA, and p75NTR
(Descamps et al, 2001b).
Enzyme-linked immunosorbent assay
Cells were seeded into 50-mm dishes in Ham’s F-12/RPMI 1640
with 2% (KYSE series) or 5% (HSA/c, SUm/c) FBS, until 70%
confluent. Then, the cells were rinsed with PBS and the medium
was replaced with serum-free Ham’s F-12/RPMI 1640 and
maintained for another 48h. The medium was clarified by
centrifugation at 3000r.p.m. for 15min and kept at  801C for
further experiments. In the meantime, cell counts were deter-
mined, followed by extraction of cellular RNA. To detect NGF in
the medium, the Emax ImmunoAssay System (Promega) was used
according to the manufacturer’s instructions. All determinations
were in triplicate, and data are the means of three independent
experiments.
Immunofluorescence staining and confocal microscopy
HSA/c cells were cultured onto collagen-coated glass coverslips
(BD bioscience, Bedford, MA, USA) and either treated for 10min
with 10mM of ionomycin (Calbiochem, EMD Biosciences, CA, USA)
or left untreated (control). After the treatment, cells were washed
twice with PBS, and fixed with 4% paraformaldehyde in PBS for
15min at room temperature, followed by postfixation with
methanol for 5min at  201C. The fixed cells were incubated with
0.3% Triton X-100 solution for 15min at room temperature and
the cells were blocked for 1h with 2% FBS in PBS at room
temperature. Subsequently, the cells were incubated with a rabbit
anti-NGF polyclonal antibody (sc-548, Santa Cruz Biotechnology
Inc.) (diluted 1:50) for 1h at room temperature. After washing
twice with PBS, the cells were incubated with a goat anti-rabbit
fluorescein isothiocyanate-conjugated secondary antibody (81–
6111, Zymed, Invitrogen Corporation) for 1h at room temperature.
The cells were washed and mounted in glycerol, and viewed under
a laser scanning confocal microscope (Axiovert 200M, Carl Zeiss
Co. Ltd, Germany).
Cell migration assay
Cell migration was determined by a micropore chamber assay.
HSA/c cells (3.0 10
4) were seeded onto the top chamber of a 24-
well micropore polycarbonate membrane filter with 8-mm pores
(Becton Dickinson Labware, Lincoln Park, NJ, USA) in serum-free
Ham’s F-12/RPMI 1640 with 0, 1, 3, 10mgml
 1 of rabbit polyclonal
anti-human b-NGF antibody (500-P85, Peprotech EC, London,
UK) for neutralisation of NGF activity, with normal rabbit IgG
(500-P00, Peprotech EC) for control, or with 0, 100, or 300nM of
K252a (Alomone Labs Ltd., Jerusalem, Israel), an inhibitor of
kinase activity of TrkA. The bottom chamber was filled with Ham’s
F-12/RPMI 1640 containing 5% FBS as a chemoattractant. After
22h of incubation in a 5% CO2 humidified incubator at 371C, the
membranes were fixed and stained by Diff-Quik reagent (Inter-
national Reagents, Inc., Kobe, Japan), and the cells on the upper
surface were carefully removed with a cotton swab. Cell migration
was quantified by counting all migrated cells in each membrane.
Transient transfection of NGF-small interfering RNA
siTrio (THF27A-345), a mixture of three targeted small interfering
RNAs (siRNA), was purchased from B-Bridge International, Inc.
(Sunnyvale, CA, USA). Sequences of the oligonucleotide targeted
to NGF were 50-ggacuaaacuucagcauucTT-30 (sense), 50-gaaugcu
gaaguuuaguccTT-30 (antisense); 50-gggcagacccgcaacauuaTT-30
(sense), 50-uaauguugcgggucugcccTT-30 (antisense); and 50-ccaca
gacaucaagggcaaTT-30 (sense), 50-uugcccuugaugucuguggTT-30
(antisense). siTrio (200nM) or nonspecific RNA for control was
transfected into HSA/c using Oligofectamine reagent (Invitrogen
Corporation) and Opti-MEM I medium (Invitrogen Corporation)
according to the manufacturer’s instructions. To confirm the
efficiency of siRNA, we extracted protein and RNA after 48h after
transfection. We subcultured cells for migration assay at the same
time. For enzyme-linked immunosorbent assay (ELISA), 24h after
transfection the medium was replaced with serum-free Ham’s F-
12/RPMI 1640 and maintained for another 48h. Samples were then
obtained.
RESULTS
Expression of NGF and its receptors in OESCC specimens
We first examined the expression of NGF in OESCC using
immunohistochemical techniques. Consistent with the previous
study (Zhu et al, 2000), NGF was expressed in the cytoplasm of
OESCC cells and normal epithelial cells. Nerve growth factor
staining intensity was graded into two groups; strong and weak
expression (Figure 1A, D). We also examined the expression of
TrkA (Figure 1B, E) and p75NTR (Figure 1C, F). Among the 109
OESCC specimens, 63 (57.8%) specimens had strong NGF
expression, 76 (69.7%) specimens had strong TrkA expression,
and 51 (46.8%) specimens had positive p75NTR expression.
Correlations between NGF expression and various prognostic
factors, such as pTNM pathological classification, histopathologi-
cal grading, stage grouping, curability, and expression of TrkA and
p75NTR were investigated (Table 1). Strong NGF expression was
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sassociated with positive lymph node metastasis (P¼0.005),
positive distant metastasis (P¼0.017), poorer tumour differentia-
tion (P¼0.033), and higher TNM staging (P¼0.025). Moreover,
strong NGF expression was significantly associated with strong
TrkA expression (P¼0.032) and negative p75NTR expression
(P¼0.033). There was no significant association between NGF
expression and other factors including age, gender, extent of the
tumour, and tumour location. Calculation of survival by the
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Figure 1 Typical immunohistochemical staining results of NGF, TrkA, and p75NTR for 109 OESCC patients. Each staining intensity was graded into two
groups: (A and D) representative of strong and weak NGF expression, respectively; (B and E) representative of strong and weak TrkA expression,
respectively; (C and F) representative of negative and positive expression of p75NTR, respectively. (A–C) are sections of poorly differentiated squamous
cell carcinoma. (D–F) are sections of well-differentiated squamous cell carcinoma. Original magnification was  400. Scale bar is 50mm. (G) Overall survival
of patients classified according to the immunoreactivity of NGF. Overall survival analysis using the Kaplan–Meier method revealed that the survivalo f
patients with tumours strongly expressing NGF was significantly poorer than that of patients with tumours weakly expressing NGF (log-rank P¼0.019).
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sKaplan–Meier method revealed that strong NGF expression was
significantly associated with poorer survival (P¼0.019)
(Figure 1C), but it was not an independent prognostic factor in
multivariate analysis using Cox’s regression model (data not
shown). In this study, the only significant association found
between either TrkA or p75NTR expression and clinicopathologi-
cal factors investigated was the positive expression of p75NTR and
negative lymph node metastasis (P¼0.0009). TrkA and p75NTR
were not shown to be prognostic factors (data not shown).
Semiquantitative RT–PCR
To reveal the expression levels of NGF, TrkA, and p75NTR mRNA
in OESCC, we analysed frozen tissue samples obtained from 19
patients with OESCC using semiquantitative RT–PCR, as de-
scribed in Materials and Methods. Nerve growth factor mRNA
expression was higher in the tumour portion than the normal
epithelium portion in 89% (17 of 19) of the patients, and TrkA
mRNA expression level was higher in the tumour portion in
84% (16 of 19) of the patients. The average tumour to normal
epithelium expression ratio (T/N ratio) was 2.6171.57 and
1.6470.71, respectively, whereas 42% (8 of 19) had lower
p75NTR mRNA level in the tumour portion, with average
p75NTR T/N ratio of 1.4370.94. The distribution of T/N ratio of
NGF, TrkA, and p75NTR mRNA expression among the 19 patients
is shown in Figure 2.
Expression of NGF, TrkA, and p75NTR in OESCC cell lines
Next, we examined the expression of NGF, TrkA, and p75NTR in
five OESCC cell lines (KYSE-150, KYSE-170, KYSE-1170, HSA/c,
and SUm/c). The mRNA expression and protein expression of
NGF, TrkA, and p75NTR were consistently detected by RT–PCR
(Figure 3A) and Western blot (Figure 3B). Phosphorylated TrkA
was also detected in all five OESCC cell lines on Western blot.
Although the expression levels of TrkA appeared to be similar
among five cell lines, the expression levels of phosphorylated TrkA
was clearly higher in KYSE150, HSA/c, and Sum/c, all of which
expressed higher amount of NGF than the remaining two cell lines.
Specifically, the amount of NGF proteins detected in HSA/c and
SUm/c was much higher than other three cell lines.
NGF secretion from OESCC cell lines
The secretion of NGF by OESCC cell lines (KYSE-150, KYSE-170,
KYSE-1170, HSA/c, SUm/c) was detected by ELISA, which clearly
demonstrated that all OESCC cell lines secreted NGF (Figure 3C),
and that the amount of NGF secreted was positively related to the
mRNA expression levels of NGF (Figure 3D). HSA/c and SUm/c
secreted relatively higher levels of NGF compared with the KYSE
series. This finding was consistent with the results of Western blot
analysis (Figure 3B).
To confirm that NGF is indeed secreted by viable OESCC cells,
we used ionomycin, which is a known inducer of exocytosis
(Kauffman et al, 1980), to reveal a release of NGF from OESCC
cells. As shown in Figure 3E, after stimulation with ionomycin,
cytoplasmic concentration of NGF was dramatically reduced,
which strongly suggested that NGF was secreted by exocytosis.
Effects of neutralising antibody against NGF and inhibitor
of TrkA on motility of OESCC cell line
To assess the role of NGF overexpression in OESCC cells, we used
HSA/c, an OESCC cell line derived from lymph fluid in the thoracic
duct and has a high potential for lymph node metastasis (Nakaji
Table 1 Relations between NGF expression and clinicopathological
characteristics
NGF strong (n¼63) NGF weak (n¼46) P-value
Age (years)
o63 28 (25.7%) 27 (24.8%) 0.142
X63 35 (32.1%) 19 (17.4%)
Gender
Male 52 (47.7%) 39 (35.8%) 0.755
Female 11 (10.1%) 7 (6.4%)
TNM
T1/T2 24 (22.0%) 21 (19.3%) 0.429
T3/T4 39 (35.8%) 25 (22.9%)
N0 14 (12.8%) 22 (20.2%) 0.005
N1 49 (45.0%) 24 (22.0%)
M0 46 (42.2%) 42 (38.5%) 0.017
M1
a 17 (15.6%) 4 (3.7%)
TNM stage
I/IIA–B 22 (20.2%) 26 (23.9%) 0.025
III/IV 41 (37.6%) 20 (18.3%)
Histology
Well/moderately 42 (38.5%) 39 (35.8%) 0.033
Poorly 21 (19.3%) 7 (6.4%)
Location
b
U 8 (7.3%) 9 (8.3%) 0.553
M 34 (31.2%) 21 (19.3%)
L 21 (19.3%) 16 (14.7%)
TrkA expression
Weak 14 (12.8%) 19 (17.4%) 0.032
Strong 49 (45.0%) 27 (24.8%)
p75NTR expression
Negative 39 (35.8%) 19 (17.4%) 0.033
Positive 24 (22.0%) 27 (24.8%)
aM1: All cases are with distant lymph nodes metastasis.
bU¼cervical and upper
thoracic oesophagus; M¼middle thoracic oesophagus; L¼lower thoracic and
abdominal oesophagus.
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Figure 2 Semiquantitative RT–PCR. Ratio of NGF, TrkA, and p75NTR
mRNA expression in the tumour portion (T) and corresponding normal
epithelium (N) in 19 OESCC patients (T/N ratio) was examined. In 89%
(17 of 19) of the patients, NGF mRNA levels were higher in the tumour
portion and in 84% (16 of 19) TrkA mRNA levels were higher; 42% (eight
of 19) of the pateints had lower p75NTR mRNA levels in the tumour
portion.
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set al, 1999; Ito et al, 2006). Thus far, it has been revealed that
HSA/c produced and secreted quite high amounts of NGF
(Figure 3B-E). We blocked the NGF-TrkA pathway by using a
neutralising antibody or K252a, a specific inhibitor of TrkA. Ten
mgml
 1 neutralising antibody of NGF decreased motility of HSA/c
cells significantly to 70%, and 100 and 300nM of K252a decreased
migration of HSA/c cells to 70 and to 30%, respectively, as
compared with control cells on migration assays, both reaching
statistical significance (Figure 4A and B). We confirmed that
neither neutralising antibody nor K252a affected the proliferation
of OESCC cell lines (data not shown).
Effects of transient transfection with NGF-siRNA on
motility of OESCC cell line
To further confirm the role of NGF in cell motility, we used siRNA
for transient transfection. The NGF expression level was efficiently
reduced by 85% on ELISA (Figure 5A) and Western blot
(Figure 5B). In fact, after transfection with siRNA, the NGF
expression decreased to the level nearly undetectable by Western
blot. Western blot also revealed reduction of phosphorylated TrkA
(Figure 5B). There was also reduced expression of TrkA after
siRNA transfection, but its reduction rate is less than that of
phospho-TrkA, as clearly shown by NGF-siRNA/NSC expression
ratio. Next, we examined the ability of NGF-siRNA treatment to
affect cell migration. Downregulation of NGF dramatically reduced
cell motility as compared with control cells; cell migration was
decreased by 70% (Figure 5C). In the meantime, NGF down-
regulation did not affect cell proliferation (data not shown).
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Figure 4 (A) Transwell migration assay of HSA/c with NGF neutralising
antibody. The asterisk indicates significant difference (*Po0.05 the Tukey–
Kramer test) vs 0mgml
 1.( B) Transwell migration assay of HSA/c with
K252a (tyrosine kinase inhibitor for TrkA). K252a (100nM) reduced cell
migration significantly as compared with 0nM. Moreover, 300nM of K252a
reduced cell migration significantly as compared with 0 and 100nM. The
asterisk indicates significant difference (*Po0.05, **Po0.05, the Tukey–
Kramer test).
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sDISCUSSION
In this study, we investigated the expression of NGF and its
receptors in a large number of OESCC specimens and found that
NGF was strongly expressed in 63 of 109 (57.8%) specimens. When
the expression of NGF by OESCC was compared with clinico-
pathological data, it became apparent that strong NGF expression
correlated with positive lymph node metastasis, positive distant
metastasis, poorer tumour differentiation, higher TNM staging,
and poorer survival. Furthermore, upregulation of NGF mRNA was
also confirmed in 89% of OESCC patients.
There is only one study about the role of NGF in oesophageal
cancer, showing that downregulation of NGF was associated with
poorer tumour differentiation and advanced tumour stage (Zhu
et al, 2000). However, among 41 patients of their study, nearly half
of them had adenocarcinoma, thus number of OESCC patients is
much lower than our study, which might lead to insufficient
evaluation. On the contrary, as our results, most of previous
reports regarding other cancers have shown the positive relation-
ship between malignant potential of tumours and expression of
NGF or its receptors (Geldof et al, 1998; Schneider et al, 2001; Zhu
et al, 2001, 2002; Sakamoto et al, 2001a,b; Kishibe et al, 2002;
Davidson et al, 2003; Dolle et al, 2003).
The relation between two specific NGF receptors, TrkA and
p75NTR, remains unclear. The expression of TrkA is considered a
favourable prognostic factor in several types of cancer (Kramer
et al, 1996; Combaret et al, 1997; Descamps et al, 2001a), whereas
activation of TrkA by phosphorylation correlates with a poorer
clinical outcome in serous ovarian carcinoma (Davidson et al,
2003). Results of the current study revealed that higher expression
of NGF is correlated with increased production of phospho-TrkA
in OESCC, and suppression of NGF expression resulted in
decreased expression of phospho-TrkA in vitro. (Figures 3B and
5B). Moreover, immunohistochemical study of 109 OESCC clinical
samples revealed that NGF strong expression was associated with
strong TrkA expression and negative p75NTR expression (Table 1).
We also performed semiquantitative RT–PCR for TrkA and
p75NTR as well as NGF, which revealed that NGF and TrkA were
expressed higher in the tumour portion than normal epithelium in
89 and 84% of patients, respectively, whereas p75NTR expression
was lower in the tumour portion in 42% of patients (Figure 2).
These results support our immunohistochemical study and imply
that NGF-TrkA pathway is important for malignant potential of
OESCC. Interestingly, progressive loss of p75NTR expression has
been reported in more advanced lesions of several types of cancer
(Pflug et al, 1992; Davidson et al, 2001, 2004). It may be possible
that NGF stimulate TrkA rather than p75NTR in aggressive cancers
with high malignant potential, as results of a study by Sakamoto
et al (2001a) showed that patients with NGFþ and p75NTR  had
poorer survival in breast cancer. Further study is needed to clarify
whether NGF shifts its receptor to TrkA from p75NTR.
Next, we examined the role of NGF expression in OESCC cell
lines. All five OESCC cell lines studied expressed NGF, TrkA,
and p75NTR mRNA as well as protein. All of these OESCC cell
lines showed TrkA phosphorylation on Western blot. Moreover,
detectable levels of NGF were found in the conditioned media of
the OESCC cell lines. The cellular motility was inhibited by NGF
neutralising antibody, K252a (a TrkA inhibitor), and NGF-siRNA.
The ability to inhibit cell motility was less with neutralising anti-
NGF antibody than with K252a or NGF-siRNA, probably because it
is difficult to neutralise NGF completely even with a specific
antibody. Our results confirmed that the OESCC cell lines secrete
biologically active NGF, which acts on TrkA in an autocrine
manner to promote OESCC cell migration. These are compatible
with our clinical findings from more than 100 cases of
immunohistochemistry that overexpression of NGF is associated
with lymph node metastasis and associated with poorer clinical
outcome. To our knowledge, this is the first time to demonstrate
NGF autocrine secretion in gastrointestinal cancer, although
several previous studies have shown NGF autocrine secretion in
other types of cancer (Weeraratna et al, 2000; Zhu et al, 2001, 2002;
Dolle et al, 2003), as well as in noncancerous tissues (Torcia et al,
1996; Pincelli and Marconi, 2000).
One candidate molecule that promotes cell movement in
the NGF pathway is Rho-guanine nucleotide exchange factor
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Figure 5 Transient transfection of HSA/c with NGF-siRNA. (A) NGF-
siRNA significantly reduced NGF secretion from HSA/c by 85% in ELISA
(*Po0.0001). Twenty-four hours after transient transfection of NGF-
siRNA, medium was changed to serum-free medium. At 72h after
transfection, conditioned media were collected. NSC: nonspecific control
RNA. (B) Western blot analysis for NGF, TrkA, and phospho-TrkA. After
transfection with siRNA, the NGF expression decreased to the level nearly
undetectable. Western blot also revealed reduction of phosphorylated
TrkA. There was also reduced expression of TrkA after siRNA transfection,
but its reduction rate is less than that of phospho-TrkA, as clearly shown by
NGF-siRNA/NSC expression ratio. (C) Transwell migration assay. Nerve
growth factor-siRNA significantly decreased cell migration (*P¼0.0009).
NGF in oesophageal squamous cell carcinoma
S Tsunoda et al
328
British Journal of Cancer (2006) 95(3), 322–330 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s(Rho-GEF) Trio. It is known to be involved in the NGF pathway
(Estrach et al, 2002), and activates RhoA with its GEF2 domain
(Debant et al, 1996; Bateman and Van Vactor, 2001). Further
investigation is necessary to unveil the involvement of Rho-GEF
Trio in NGF pathway of OESCC cells.
Given the recent success of trastuzumab (Herceptin), imatinib
mesylate (Gleevec), and gefitinib (Iressa) as chemotherapeutic
agents, tyrosine kinase is definitely a promising target of molecular
targeted medicine (Ross et al, 2004) for cancer therapy. Nerve
growth factor–TrkA interactions could thus be a new therapeutic
target. Nerve growth factor-siRNA might be one good option for
OESCC treatment once tumour-specific siRNA delivering systems
become available.
In summary, results of our immunohistochemical study
of 109 OESCC patients clearly suggest that NGF is an
unfavourable prognostic factor in OESCC. Furthermore,
NGF–TrkA interaction promotes cellular motility in an autocrine
manner, which in turn contributes to poor prognosis of
NGF-secreting OESCC. However, it has also been shown that
chemical agents that block NGF–TrkA interaction can inhibit
cellular motility, leaving the possibility that these agents might be
able to improve clinical prognosis of NGF-producing OESCC.
These findings suggest that NGF is of potential interest not only
as a prognostic factor, but also as a novel therapeutic target in
OESCC.
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